# Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers

> **NCT01026597** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** REGN727
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01026597
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01026597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01026597, "Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01026597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*